当前治疗策略对那他珠单抗停用后疾病再激活无影响：那他珠单抗停用后第一年不同方法的比较分析
No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.
作者信息
Capobianco M, di Sapio A, Malentacchi M, Malucchi S, Matta M, Sperli F, Bertolotto A
机构信息
Regional Multiple Sclerosis Centre, San Luigi Gonzaga Hospital, Orbassano, Italy.
出版信息
Eur J Neurol. 2015 Mar;22(3):585-7. doi: 10.1111/ene.12487. Epub 2014 Jul 3.
BACKGROUND AND PURPOSE
Natalizumab discontinuation induces the recurrence of multiple sclerosis disease activity: currently no therapeutic approach has been found able to abolish disease reactivation.
METHODS
The recurrence of disease activity after natalizumab discontinuation was retrospectively evaluated in 79 patients who had been treated with immunomodulating agents, other first-line therapies, fingolimod or not treated.
RESULTS
No differences have been found in clinical or magnetic resonance imaging recurrence of disease activity amongst the groups. Interestingly, no disease reactivation was observed only in one patient treated for 6 months with monthly pulses of cyclophosphamide.
CONCLUSION
Disease modifying treatment or 'no treatment' is unable to abolish disease activity reactivation after natalizumab discontinuation.
背景与目的
停用那他珠单抗会诱发多发性硬化疾病活动复发：目前尚未发现能够消除疾病再激活的治疗方法。
方法
对79例接受过免疫调节药物、其他一线治疗、芬戈莫德治疗或未接受治疗的患者，回顾性评估停用那他珠单抗后疾病活动的复发情况。
结果
各治疗组间在疾病活动的临床或磁共振成像复发方面未发现差异。有趣的是，仅1例接受每月一次环磷酰胺冲击治疗6个月的患者未观察到疾病再激活。
结论
疾病修饰治疗或“不治疗”无法消除停用那他珠单抗后的疾病活动再激活。
Zotero 插件